Category Archives: News

Carlyle partners with Rabo Investments to invest in SurePay

Carlyle

Utrecht, Netherlands and London, UK – 3 June 2025 – Carlyle Europe Technology Partners (“CETP”), in partnership with Rabobank’s investment arm Rabo Investments, today announced a strategic growth investment in SurePay, a European leader in payment verification software.

Founded within Rabobank in 2016 and headquartered in the Netherlands, SurePay is a leading provider of payment verification technology solutions to financial institutions and corporates across Europe and the UK. The company reduces fraudulent and misdirected payments through its trusted real-time IBAN-name check, Confirmation-of-Payee (CoP), Verification-of-Payee (VOP), and Fraud Risk Indicator (FRI) products, supporting 200+ banks and 750+ corporate customers. Once implemented, SurePay reduces impersonation scams by 81% and erroneous payments by 67% on average. To date, SurePay has processed more than 10 billion payment checks, playing a critical role in helping clients improve payment accuracy, prevent fraud, address continuously evolving regulatory and compliance demands, and optimise operational efficiencies.

With the backing of Carlyle and Rabo Investments, SurePay plans to further expand its suite of payment verification and fraud prevention solutions and broaden its geographic presence across Europe and beyond, with a continued focus on delivering highly reliable services to its blue-chip customers.

David-Jan Janse, CEO and co-founder of SurePay, said:
“We are thrilled to welcome Carlyle as a strategic partner for the next stage of our journey. The team is grateful to Connected Capital and Iris Capital for their partnership since 2021, and the valuable experience they have brought in scaling B2B SaaS businesses and supporting breakout technology ventures like ours. With Carlyle’s deep experience in financial infrastructure and enterprise software, they are the ideal partner to join Rabobank in supporting our ambition to strengthen our leadership across Europe and the UK, and expand into other international markets. This investment is a major milestone for our team and a strong validation of the platform we have built together with top-tier financial institutions and leading corporates around the world.”

Constantin Boye, who leads the European growth equity efforts within the CETP investment advisory team at Carlyle, said:
“SurePay is a mission-critical payment verification solutions provider with a powerful combination of proven technology and deep relationships across the European and UK banking ecosystem. The team has done an exceptional job building a platform that delivers real, measurable impact in reducing fraud and improving payment accuracy for both financial institutions and corporates. We are excited to partner with Rabo Investments in supporting SurePay as they continue to scale internationally and drive innovation in this increasingly important space.”

Carlyle is investing through its CETP V fund, a €3.2 billion vehicle focused on growth-stage technology businesses across Europe. The CETP team has extensive experience in scaling European financial technology and Governance, Risk and Compliance (GRC) software platforms, with notable investments including FRS Global, ITRS, Calastone, VWD, and Trema.

Floris Onvlee, Director at Rabo Investments, added:
“Since its founding within Rabobank, SurePay has been developed to meet the highest possible financial services quality standards with best-in-class platform reliability, scalability, and security. We believe that this bank-grade heritage, which underpins the many strengths of SurePay’s current offering, has enabled the team to execute with focus, ambition, and credibility to become a European leader in payment verification. Today, their solutions are used by many of the world’s largest financial institutions and corporates, delivering meaningful impact at enterprise scale. After a fruitful partnership with Connected Capital and Iris Capital, we are proud to continue on this growth journey with the SurePay team alongside Carlyle, supporting Rabobank’s corporate venture strategy to build a stronger and more secure financial ecosystem.”

 

About SurePay
SurePay is a leading provider of payment verification technology, headquartered in the Netherlands. The company originally pioneered the IBAN-name check solution in the Dutch market in 2017 and has since expanded across Europe and the UK with its real-time Verification-Of-Payee (VOP), Confirmation-of-Payee (CoP) and Fraud Risk Indicator (FRI) solutions. SurePay serves more than 200 banks and 750 corporate customers and has processed more than 10 billion payment checks to date, playing a critical role in helping clients prevent fraud, improve payment accuracy, and meet continuously evolving compliance and regulatory demands.

 

Media Contacts
Carlyle

Nicholas Brown
nicholas.brown@carlyle.com
+44 7471037002

 

SurePay

Ramon Verweij
ramon@surepay.eu
+31 623833068

 

Rabo Investments

Hugo Nutbey
hugo.nutbey@rabobank.nl
+31 887263463

Categories: News

Tags:

CareLineLive Secures Majority Investment from Technology Investment Firm Accel-KKR

AKKR Logo

London, UK & Menlo Park, CA – June 3, 2025 — CareLineLive, an all-in-one home care management software company, has secured a majority investment from technology-focused investment firm Accel-KKR, to spur accelerated growth, expansion and product development.

Founded in 2014 by entrepreneur Josh Hough, CareLineLive provides an all-in-one cloud-based platform for homecare agencies, integrating staff scheduling, client visits, patient records and invoicing. The company currently supports hundreds of care providers across seven countries.

Across many parts of the world, the home healthcare market continues to grow. For example, the UK’s home and domiciliary care market is worth £11.5 billion, according to insurance broker PolicyBee. The Australian home healthcare market is projected to reach USD 25.7 billion by 2030, whereas the U.S. home care providers market is valued at approximately $153.7 billion in 2025.

Hough said the investment would help accelerate the company’s growth and international reach. “Our vision has always been to make homecare better for everyone through the use of technology – for providers, carers and clients,” he said.

“This investment helps bring that future closer. Accel-KKR’s long track record of helping software companies grow is what I am most excited about. Their experience and resources will help us to grow our team, enhance our product, and deliver even more value to our customers.”

A portion of the funding will be used to establish a customer support presence in Australia, enabling round-the-clock service. “As our UK team finishes for the day, the Australia team will begin – meaning we’ll be able to support customers at any time of day,” Hough added.

The full transaction value has not been disclosed, but the investment also facilitates an exit for early backers Oakglen and Haatch. Hough also paid tribute to the outgoing investors: “We’re incredibly proud of the progress we’ve made over the last decade and I’d very much like to thank both Oakglen and Haatch for their support. This marks an exciting new chapter with Accel-KKR.”

Accel-KKR, which specialises in investing in enterprise software and tech-enabled businesses, cited CareLineLive’s technology and customer-centric ethos as among the key drivers behind its decision to invest in CareLineLive.

Maurice Hernandez, Managing Director at Accel-KKR, said, “No matter where they serve, home care providers want to focus on delivering responsive, respectful and personalized care. Technology can help carers and agencies improve efficiencies, maintain compliance and grow while being focused on their clients’ wellbeing. We’re excited to back CareLineLive and help Josh and his team continue to build market-leading solutions in this category.”

Hough said he and the senior management team will be remaining with the company for the foreseeable future.  “There’s a long-term plan in place, but it’s very much business as usual,” Hough added.

About CareLineLive
Founded in 2014, CareLineLive provides an all-in-one cloud-based platform for homecare agencies, integrating staff scheduling, client visits, patient records and invoicing. The company currently supports hundreds of care providers across seven countries. CareLineLive is one of the few companies to meet the NHS requirements to be on the approved supplier list for Digital Social Care Records. It also integrates with GP Connect, enabling access to GP records.

About Accel-KKR
Accel-KKR is a technology-focused investment firm with $21 billion in cumulative capital commitments. The firm focuses on software and tech-enabled businesses, well-positioned for top-line and bottom-line growth. At the core of Accel-KKR’s investment strategy is a commitment to developing strong partnerships with the management teams of its partner companies and a focus on building value alongside management by leveraging the significant resources available through the Accel-KKR network. Accel-KKR focuses on middle-market companies and provides a broad range of capital solutions, including buyout capital, minority-growth investments, and credit alternatives. Accel-KKR also invests across various transaction types, including private company recapitalizations, divisional carve-outs and going-private transactions. Accel-KKR’s headquarters is in Menlo Park, with offices in Atlanta, Chicago, London, and Mexico City. For more, visit accel-kkr.com.

Categories: News

Tags:

Gilde Healthcare participates in $75 Million Series D round of SpyGlass Pharma to Advance Its Long-term Drug Delivery Platform for Glaucoma Patients

GIlde Healthcare
Aliso Viejo, CA (United States)

SpyGlass Pharma, a privately-held ophthalmic biotechnology company, announced the closing of a $75 million Series D financing round. SpyGlass’ Drug Delivery Platform aims to provide multiple years of medical therapy, addressing the need for long-term management of glaucoma and other chronic ophthalmic diseases.

Gilde Healthcare joined the Series D as a new investor alongside Sands Capital and existing investors: New Enterprise Associates (NEA), RA Capital, Vensana Capital, Samsara BioCapital and Vertex Ventures HC. The funding will support the advancement of SpyGlass Pharma’s cutting-edge Drug Delivery Platform through the readout of two registrational Phase III trials, set to begin later this year.

“We appreciate the strong support from our new and existing investors, underscoring their confidence in our innovative Drug Delivery Platform,” said Patrick Mooney, CEO of SpyGlass Pharma. “We are excited to advance our platform through pivotal Phase III trials as we accelerate our commitment to addressing significant unmet needs for ophthalmic patients.

“We believe our approach represents a paradigm shift in the treatment of eye diseases, such as glaucoma, with significant advantages compared to currently commercialized therapies,” said Dr. Malik Y. Kahook, MD, Co-Founder and President of SpyGlass Pharma. “The long-term safety and efficacy demonstrated from both the first-in-human feasibility trial and the Phase II, multi-center, randomized clinical trial showing significant and sustained intraocular pressure-lowering in glaucoma patients, is compelling.”

About SpyGlass Pharma
The SpyGlass Drug Delivery Platform with bimatoprost is designed to deliver 3 years of bimatoprost to targeted tissues. Patients in the first-in-human study will continue to be followed over time, and the Company plans to share 24 month follow up data at the American Academy of Ophthalmology meeting later this year. SpyGlass completed enrollment in a Phase I/II study in the United States to investigate the safety and efficacy of its platform in a larger patient pool. SpyGlass looks forward to working closely with the U.S. Food and Drug Administration (FDA) to advance the program through Phase III clinical trials and ultimately to commercial approval. SpyGlass operates from its facilities in California and can be found online at www.spyglasspharma.com.

About Gilde Healthcare
Gilde Healthcare is a transatlantic specialist investment firm managing over €2.6 billion across two fund strategies: Venture&Growth and Private Equity. The Venture&Growth fund of Gilde Healthcare invests in fast growing companies active in digital health, medtech and therapeutics, based in Europe and North America. The Private Equity fund of Gilde Healthcare participates in profitable lower mid-market healthcare companies based in North-Western Europe. For more information, visit the company’s website at www.gildehealthcare.com.

Categories: News

Tags:

KKR Provides $600 Million Financing to Indian Conglomerate Manipal Group

KKR

Transaction marks KKR’s latest and largest credit investment in India

MUMBAI, India–(BUSINESS WIRE)– KKR, a leading global investment firm, and Manipal Education and Medical Group (“MEMG” or “Manipal Group”), a major diversified conglomerate in India, today announced a $600-million financing arranged by KKR Capital Markets and anchored by KKR’s private credit and insurance platforms to the Manipal Group. The investment will enable the Manipal Group to accelerate its corporate expansion and growth objectives by providing flexible, structured capital matched to its long-term strategic needs.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250601919977/en/

The Manipal Group is a leading conglomerate in India with various institutions and major businesses across the healthcare, education, and health insurance sectors, including Manipal Health Enterprises, one of India’s top multispecialty hospitals chains in India.

KKR’s Asia Pacific Credit platform seeks to provide, among other private credit strategies, bespoke solutions to high-quality companies, entrepreneurs, promoters and sponsors that harness the strength of KKR’s private markets investment capabilities and its expertise as one of the largest alternative credit managers globally.

Gaurav Trehan, Co-Head of KKR Asia Pacific and Head of Asia Private Equity, KKR said, “We are pleased to deepen our relationship with the Manipal Group and Dr Ranjan Pai, who have established one of India’s pre-eminent and homegrown businesses, as they continue to deliver on their long-term vision. The Manipal Group has built a strong reputation over the decades as one of India’s healthcare and education leaders, and we look forward to supporting and contributing to their continued success.”

Dr. Ranjan Pai, Chairman of Manipal Education and Medical Group, said, “We are proud to welcome KKR as a strategic partner as we continue to build on Manipal’s legacy in healthcare and education. KKR’s longstanding India focus and flexible capital approach, as well as alignment with our long-term vision, present a strong fit for us.”

Diane Raposio, Partner and Head of Asia Credit and Markets at KKR, added, “This transaction underscores the strength of our global credit platform and our ability to provide strategic, scaled capital solutions to leading businesses. India is a priority market for our credit strategy, and we look to build on this momentum to be a partner of choice to more high-quality companies like Manipal on their growth ambitions.”

KKR is making its investment from its Asia Pacific Credit strategy and insurance platform. Since 2019, KKR has committed more than $8 billion across around 60 credit investments under its Asia Pacific Credit strategy, accounting for a total transaction volume of more than $21 billion.

Additional details of the transaction are not disclosed.

About KKR

KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR’s insurance subsidiaries offer retirement, life and reinsurance products under the management of Global Atlantic Financial Group. References to KKR’s investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR’s website at www.kkr.com. For additional information about Global Atlantic Financial Group, please visit Global Atlantic Financial Group’s website at www.globalatlantic.com.

About Manipal Education and Medical Group (MEMG)

Founded in 1953 by Padma Shri Dr TMA Pai, MEMG has evolved into a diversified conglomerate, with a strong presence in healthcare, education and health insurance in India and globally. MEMG’s operations touch the lives of over 20 million people annually with Manipal Hospitals scaling up to become the largest tertiary network in India. MEMG’s flagship University, Manipal Academy of Higher Education has been recognized as an Institute of Eminence by the Government of India. Claypond Capital, the family office of Dr. Pai and the investing arm of MEMG has been one of the more prolific investing family offices in India in the last 18 months. Their marquee investments include Aakash, BPL Medical, BlueStone, Easy Home Finance, First Cry, Finnable, InCred Finance, NSE, Panacea Medical, PharmEasy, Purpple, Recykal, SSI Innovations and Zepto.

Media Contacts

For KKR Asia Pacific
Wei Jun Ong
+65 6922 5813
WeiJun.Ong@kkr.com

For Manipal Group
Shyam Powar
+91 98804 75000
Shyam.Powar@claypondcapital.com

Source: KKR

 

Download PDF

Categories: News

Tags:

EQT Real Estate acquires a five-building logistics portfolio across three locations in Southern France

Picture

  • Acquisition of five logistics assets totaling approximately 148,000 square meters
  • Let to nine tenants, this highly reversionary portfolio has a weighted average remaining lease term to break of less than two years
  • With this transaction, EQT Real Estate will meaningfully increase its exposure to the core Southeast and Southwest France logistics markets

EQT Real Estate is pleased to announce that EQT Exeter Logistics Value Fund IV has acquired a best-in-class logistics portfolio of five warehouses.

The portfolio of big-box assets totals approximately 148,000 square meters and are located in the key Southern France submarkets of Avignon and Toulouse. The warehouses’ respective locations offer proximate access to core population centres via key motorways, including the A20 and the A7 which provide connectivity to Marseille and Lyon.

The properties feature Grade A technical specifications, including eaves heights averaging over ten meters, as well as ample loading and maneuvering features. The portfolio benefits from a strong, global diversified tenant base and is well-suited to meet the growing needs of today’s modern logistics users.

This acquisition strengthens EQT Real Estate’s exposure to core Southern France submarkets, which are structurally undersupplied and continue to experience resilient demand. These are highly desirable occupier markets benefiting from the excellent connectivity which supports supply chains along the Atlantic and Mediterranean coasts.

John Toukatly, Partner, Chief Investment Officer, European Logistics at EQT Real Estate, said: “We are excited to add these top-tier logistics properties to our portfolio. Situated in supply-constrained markets, these assets are highly attractive to a wide range of major big-box tenants and are well aligned with EQT Real Estate’s strategy of acquiring modern, high-potential logistics properties in underserved areas across Europe. With our operational and asset management capabilities, we intend to further enhance the value of this high-quality portfolio.”

EQT Real Estate was advised by PwC (financial and tax), Gide and GMH Notaires (legal and notarial), CBRE (commercial), Tauw (environmental), AMF (ICPE and PM) and Gleeds (technical and ESG).

Contact
EQT Press Office, press@eqtpartners.com

Downloads

About EQT Real Estate
EQT is a purpose-driven global investment organization with EUR 273 billion in total assets under management (EUR 142 billion in fee-generating assets under management) as of 31 March 2025, divided into two business segments: Private Capital and Real Assets. EQT supports its global portfolio companies and assets in achieving sustainable growth, operational excellence, and market leadership. Within EQT’s Real Assets segment, EQT Real Estate acquires, develops, leases, and manages logistics and residential properties in the Americas, Europe, and Asia. EQT Real Estate owns and operates over 2,500 properties and 540 million square feet, with over 440 experienced professionals across 50 locations globally.

More info: www.eqtgroup.com
Follow EQT Real Estate on LinkedIn

Categories: News

Tags:

bluebird bio Announces Completion of Acquisition by Carlyle and SK Capital

Carlyle

New management, led by David Meek, is committed to rapidly scaling access to lifechanging gene therapies

Significant capital commitment from Carlyle and SK Capital will enable bluebird to grow and accelerate patient access

bluebird will focus on expanding manufacturing capacity and improving the treatment experience for patients and providers

SOMERVILLE, Mass. — June 2, 2025 — bluebird bio (NASDAQ: BLUE) (“bluebird”), a pioneer in gene therapies for severe genetic diseases, today announced the completion of its sale to funds managed by global investment firms Carlyle (NASDAQ: CG) and SK Capital Partners, LP (“SK Capital”). With the closing of the transaction, bluebird’s common stock has ceased trading and will no longer be publicly listed. Carlyle and SK Capital have provided significant primary capital to support and scale bluebird’s commercial delivery of gene therapies for patients with sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy.

David Meek, who became Chief Executive Officer of bluebird at close, said, “Today marks the beginning of a new era for bluebird as its go-forward financial backing and leadership team will better enable all stakeholders to realize the full potential of our revolutionary therapies. Historically, bluebird has excelled as a scientific innovator and should be very proud of the many achievements it has delivered to patients. Our vision is to further that legacy of scientific excellence while improving the commercial execution of our approved products to rapidly expand access to lifechanging gene therapies.”

“We are excited to back bluebird in partnership with SK Capital. We believe providing bluebird the necessary funding along with the new leadership team will help bluebird realize its full potential,” said Joe Bress, Carlyle Partner and Global Co-Head of Healthcare. Bali Muralidhar, Co-Managing Partner and Chief Investment Officer & COO of Abingworth, Carlyle’s life sciences investment franchise, added, “There is an incredible opportunity to bring bluebird’s groundbreaking therapies to more patients in need, and we look forward to advancing bluebird in its mission.”

“SK Capital looks forward to partnering with David and his team as well as Carlyle to scale bluebird’s pioneering gene therapies that can make a lifechanging difference for patients around the world,” said Aaron Davenport, Managing Director at SK Capital, adding, “We believe our deep collective experience in manufacturing and commercializing therapies can help drive the next chapter of bluebird’s growth.”

Incoming Team Bolsters Commercial Gene Therapy Experience 

The company’s momentum is reinforced by a deeply experienced management team, led by CEO David Meek. David brings more than 30 years of leadership in life sciences, including as CEO of Mirati Therapeutics and Ipsen. David is joined by Tom Klima as Chief Commercial & Operating Officer, Debasish Roychowdhury, M.D., as Chief Medical Officer, Wendy DiCicco as Chief Financial Officer, and Ellen Forest as Chief People Officer. Additional details are available at https://www.bluebirdbio.com/about-us/leadership.

From Scientific Breakthroughs to Delivery at Scale

With the transaction now closed, bluebird is prioritizing expanding its manufacturing infrastructure, streamlining the patient journey, supporting treatment centers, and strengthening its payer partnerships. The acquisition provides the strategic and financial backing needed to meet rising demand and drive commercial and operational excellence across the organization.

“bluebird has demonstrated what’s possible through effective gene therapy,” David added. “Now we will build the ecosystem to ensure every patient who needs these therapies can access them.”

About bluebird bio

bluebird bio is a commercial-stage biotherapeutics company focused on developing and delivering gene therapies for severe genetic diseases. With more than a decade of scientific leadership in gene therapy and three FDA-approved therapies for sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy, the company is committed to ensuring access, reliability, and patient-centered care. bluebird is headquartered in Somerville, Massachusetts.

About Carlyle

Carlyle (NASDAQ: CG) is a global investment firm with deep industry expertise that deploys private capital across its business and conducts its operations through three business segments: Global Private Equity, Global Credit and Carlyle AlpInvest. With $453 billion of assets under management as of March 31, 2025, Carlyle’s purpose is to invest wisely and create value on behalf of its investors, portfolio companies, and the communities in which we live and invest. Carlyle employs more than 2,300 people in 29 offices across four continents. Further information is available at www.carlyle.com. Follow Carlyle on X @OneCarlyle and LinkedIn at The Carlyle Group.

About SK Capital

SK Capital is a transformational private investment firm with a disciplined focus on the life sciences, specialty materials, and ingredients sectors. The firm seeks to build resilient, sustainable, and growing businesses that create substantial long-term value. SK Capital aims to utilize its industry, operating, and investment experience to identify opportunities to transform businesses into higher performing organizations with improved strategic positioning, growth, and profitability, as well as lower operating risk. SK Capital currently has approximately $10 billion in assets under management as of December 31, 2024. For more information, please visit www.skcapitalpartners.com.

Forward Looking Statement

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Such forward-looking statements are based on historical performance and current expectations and projections about bluebird’s future goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond bluebird’s control and could cause bluebird’s future goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect bluebird bio’s business, particularly those identified in the risk factors discussion in bluebird bio’s Annual Report on Form 10-K for the year ended December 31, 2024, as updated by its subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the SEC. These risks and uncertainties include, but are not limited to: the risk that the efficacy and safety results from bluebird’s prior and ongoing clinical trials will not continue or be seen in the commercial context; the risk that there is not sufficient patient demand or payer reimbursement to support continued commercialization of bluebird’s products; the risk of insertional oncogenic or other safety events associated with lentiviral vector, drug product, or myeloablation, including the risk of hematologic malignancy; and the risk that bluebird’s products will not be successfully commercialized. The forward-looking statements included in this document are made only as of the date of this document and except as otherwise required by applicable law, bluebird bio undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise.

Contacts: 

 

Bluebird

Courtney O’Leary 

+1 (978) 621-7347

coleary@bluebirdbio.com

 

Carlyle

Brittany Berliner
+1 (212) 813-4839
brittany.berliner@carlyle.com

 

SK Capital

Ben Dillon

+1 (646) 278-1353 
bdillon@skcapitalpartners.com

Categories: News

Tags:

Stout Announces New Investment Partnership With Integrum Seeking to Continue Accelerated Growth Trajectory

Audax Group

Chicago, IL – June 2, 2025 – Stout, a leading global advisory firm, announced today that it has entered into a new strategic partnership with Integrum Holdings LP (“Integrum”), a private investment firm focused on partnering with technology-enabled services companies in the financial and business services sectors. Funds advised by Integrum will invest alongside Stout’s employee shareholders to support the firm’s continued expansion objectives. As part of the transaction, Stout’s management team will remain in place, and existing employee shareholders will retain a meaningful equity stake. The transaction is expected to close in the third quarter of 2025 subject to customary closing conditions.

This new partnership follows a successful and highly collaborative relationship with Audax Private Equity (“Audax”), which first invested in Stout in November 2021 through its Flagship strategy. Over the course of the partnership, Audax provided strategic and financial support that enabled Stout to expand its platform, double headcount, complete ten acquisitions, and accelerate its growth across geographies and service lines.

“We are deeply grateful to Audax for their partnership and support over the past three and a half years,” said Craige Stout, Chief Executive Officer of Stout. “They have been instrumental in helping us further scale our business, and we are proud of what we accomplished together. As we look ahead, we are thrilled to welcome Integrum, whose team brings experience, insight, and common values that align perfectly with our ambitions for the future.”

Jeff Risius, Co-Head of Client Service at Stout, added, “This is a natural next step for Stout. Integrum’s long-term mindset, strategic expertise, and focus on people and culture make them the ideal partner for our next phase of growth.”

Tagar Olson, Founding Partner at Integrum, said, “Stout is a global firm with a reputation for excellence, a strong leadership team, and a clear growth trajectory. We are excited to support their continued expansion and to partner with a firm so deeply committed to client success and employee ownership.”

Bill Allen, Managing Director at Audax and Head of the firm’s Financial Services specialization, commented, “It has been a privilege to partner with the outstanding team at Stout. Over the past several years, we have watched the firm grow significantly in scale, capability, and market presence, all while staying true to its culture of ‘Relentless Excellence®’. We are confident that Stout is well-positioned for continued success. We wish Craige, Jeff, and the entire Stout team the very best as they begin this exciting next chapter with Integrum.”

William Blair & Company acted as financial advisor and Winston & Strawn LLP and Ropes and Gray LLP served as legal counsel to Stout.

Simpson Thacher & Bartlett LLP served as legal counsel to Integrum.

About

About Stout
Stout is a global advisory firm specializing in corporate finance, accounting and transaction advisory, valuation, and financial disputes, claims, and investigations. Stout serves a range of clients, from public corporations to privately held companies in numerous industries. Our clients and their advisors rely on our premier expertise, deep industry knowledge, and unparalleled responsiveness on complex matters. Stout is a trade name for Stout Risius Ross, LLC, Stout Advisors SA, Stout Bluepeak Asia Ltd., Stout GmbH, MB e Associati S.r.l., Stout Park Ltd, and Stout Capital, LLC, a FINRA-registered broker-dealer and SIPC member firm. Learn more at www.stout.com

About Audax Private Equity
Headquartered in Boston, with offices in San Francisco, New York, London and Hong Kong, Audax Private Equity manages three strategies: its Flagship and Origins private equity strategies, seeking control buyouts in the core middle and lower middle markets, respectively, and its Strategic Capital strategy that provides customized equity solutions to PE-backed portfolio companies to help drive continued growth. With approximately $19 billion of assets under management as of March 2025, over 290 employees, and 100-plus investment professionals, Audax has invested in 175 platforms and 1,350 add-on acquisitions since its founding in 1999. Through our disciplined Buy & Build approach, across six core industry verticals, Audax seeks to help portfolio companies execute organic and inorganic growth initiatives with the aim of fueling revenue expansion, optimizing operations, and significantly increasing equity value. For more information, visit www.audaxprivateequity.com or follow us on LinkedIn.

About Integrum
Integrum is an investment firm focused on partnering with technology-enabled services companies in the financial and business services sectors. The firm was founded by a team of proven leaders with a vision to build a different type of investing platform benefiting from their diverse and complementary backgrounds and vast relationship network. Integrum’s approach is to build a concentrated portfolio of high-conviction investments. Integrum aims to accelerate growth through investments in technology and other forms of innovation and by partnering with management teams to enhance access to talent, relationships, and capabilities.
Learn more at www.integrum.us

Categories: News

Tags:

Rezonate Music Rights enters $150 million strategic partnership with Bridgepoint to accelerate growth of premium music producer royalties platform

Bridgepoint
Rezonate Music Rights (“Rezonate”), a leading platform focused on acquiring the royalty rights of top music producers globally, has entered into a strategic partnership with Bridgepoint Credit, one of Europe’s most experienced credit managers.

The partnership will invest to up to $150 million of capital to support a pipeline of high-profile producer catalogue acquisitions, with Bridgepoint acquiring a minority stake in Rezonate’s management company as part of the transaction.

This collaboration marks a significant milestone for Rezonate, unlocking new growth avenues as it accelerates its mission to transform the music royalties sector and empower producers worldwide.

Empowering Music Producers

Rezonate was co-founded by Cam Blackwood, a multi-diamond and platinum-selling songwriter and record producer with over 7 billion streams in his catalogue, and Tom Tyler, who has over 20 years in senior financial roles at HSBC and the London Stock Exchange Group.

The team brings together deep sector experience in music production, valuation, and investment management. Rezonate offers a full suite of services designed to support music creators and investors alike, ensuring producer rights are properly valued, acquired, and developed.

Rezonate has already acquired the rights to the catalogues from leading producers who have produced music for global record-breaking artists such as U2, David Guetta, The Weekend, Dua Lipa, George Ezra, Lewis Capaldi, Snow Patrol, Ed Sheeran, Taylor Swift, Rag’n’Bone Man and Bastille.

Strategic Vision and Industry Leadership

As an innovator in the music royalties space, Rezonate believes in empowering producers not just financially, but through knowledge and mentorship, offering education, industry insights, and networking opportunities to help producers navigate the evolving music business.

The strategic partnership with Bridgepoint is a testament to Rezonate’s leadership and vision, enabling the company to further its mission of supporting music producers by providing transparent pathways to realise the value of their music and create new solutions to support their future ambitions while respecting the long-term value of their work.

Tom Tyler and Cam Blackwood, Co-founders of Rezonate, commented: “This partnership with Bridgepoint is a strong endorsement of Rezonate’s vision and the value we bring to music producers. With Bridgepoint’s support, we gain substantial firepower that will enable us to significantly accelerate our growth plans and continue to set new standards in the industry, ensuring that producers are at the heart of every decision we make. We are excited to bring a fresh and artist-aligned approach to the royalties space, starting with an incredible day-one catalogue that includes some of the most iconic tracks of the past decade.”

Rohit Dhote, Partner and Co-Head of Credit Opportunities at Bridgepoint, commented: “Rezonate offers a rare combination of high-quality income streams, downside-protected entry points and scalable platform dynamics in one of the most exciting corners of the entertainment economy. We’re backing a world-class team with unique access to producers and a clear strategy to create significant value over time. This is a compelling opportunity to build a differentiated royalty platform from the ground up.”

Advisors

Bridgepoint was advised by Latham & Watkins as Legal Advisor and EY as Tax Advisor. Rezonate was advised by Artisan as Financial Advisor and Lewis Silkin as Legal Advisor.

Bridgepoint Group is one of the world’s leading quoted private asset growth investors, specialising in private equity, infrastructure and private credit.

With over $86 billion of assets under management and a strong local presence in Europe, North America and Asia, we combine global scale with local market insight and sector expertise, consistently delivering strong returns through cycles.

Bridgepoint Advisers Limited, a subsidiary of Bridgepoint Group plc, is authorised and regulated by the Financial Conduct Authority.

Categories: News

Tags:

Carlyle partners with Rabo Investments to Invest in SurePay

Rabo Investments

Carlyle Europe Technology Partners (“CETP”), in partnership with Rabo Investments, announced a strategic growth investment in SurePay, a European leader in payment verification software. Following an earlier successful growth trajectory together with Connected Capital and Iris Capital, CETP and Rabo Investments now join forces to further expand SurePay’s suite of payment verification and fraud prevention solutions and geographical expansion.  

 Founded within Rabobank in 2016 and headquartered in the Netherlands, SurePay is a leading provider of payment verification technology solutions to financial institutions and corporates across Europe and the UK. The company reduces fraudulent and misdirected payments through its trusted real-time IBAN-name check, Confirmation-of-Payee (CoP), Verification-of-Payee (VoP), and Fraud Risk Indicator (FRI) products, supporting 200+ banks and 750+ corporate customers.  

 David-Jan Janse, CEO and co-founder of SurePay: 

“We are thrilled to welcome Carlyle as a strategic partner for the next stage of our journey. With Carlyle’s deep experience in financial infrastructure and enterprise software, they are the ideal partner to join Rabo Investments in supporting our ambition to strengthen our leadership across Europe and the UK, and expand into other international markets. This investment is a major milestone for our team and a strong validation of the platform we have built together with top-tier financial institutions and leading corporates around the world.” 

 More about SurePay: Home • SurePay 

Categories: News

Tags:

QUEST SOFTWARE ANNOUNCES NEW $350 MILLION CAPITAL INFUSION TO ACCELERATE AI INNOVATION AND GROWTH

Clearlake

Austin, TX – May 30, 2025 – Quest Software, a global leader in data management, identity security and platform modernization, backed by Clearlake Capital Group, L.P. (together with its affiliates, “Clearlake”), today announced the closing of a refinancing transaction of its outstanding debt with a majority of holders of its existing first lien and second lien term loans. It includes a new capital infusion of $350 million by Quest’s existing lenders, which will help accelerate Quest’s artificial intelligence (AI) innovation and growth initiatives. Participation in the transaction is open to remaining holders.

The $350 million of new term loans mature at the same time as Quest’s existing and refinanced first lien term loans in February 2029. Additionally, Quest extended the maturity of its revolving credit facility to November 2028 and de-levered its balance sheet, strengthening its liquidity position and securing additional financial flexibility to pursue the company’s growth strategy. This investment comes at a pivotal moment for Quest, as organizations across all industries are seeking trusted partners to help navigate the complexities of AI adoption.

“We thank our investors and lenders for their continued support, which we believe signals their confidence in our ability to leverage AI market opportunities,” said Tim Page, CEO of Quest. “We believe AI represents not just a technological shift but a fundamental transformation in how businesses create value. With most of the Fortune 500 companies using Quest Software for data management and identity security, we have an understanding of customer environments and requirements that drives our AI priorities and accelerated investments.”

“We are pleased with the completion of this transaction for Quest and all of its stakeholders including employees, shareholders and lenders,” said Behdad Eghbali, Co-Founder and Managing Partner, and Prashant Mehrotra and Paul Huber, Partners at Clearlake. “We believe this is an especially exciting time for the Company as the market undergoes transformation driven by the adoption of AI, the proliferation of data and the ever-evolving need for cyber resiliency, and we look forward to continuing to partner with the Quest team to accelerate growth and elevate its market position.”

“This transaction will provide enhanced investment and liquidity, allowing us to innovate and expand our suite of identity protection products,” said Mark Logan, CEO of One Identity, a standalone and independent business unit within Quest, specializing in identity and access management (IAM), privileged access management (PAM), and identity governance administration (IGA). “With AI playing an increasingly vital role in the IAM, PAM, and IGA sectors, our focus remains on delivering cutting-edge solutions that help organizations protect and manage identities effectively. We are excited to better serve customers seeking comprehensive identity management solutions and fortify our ability to respond to evolving market demands.”

This investment will support Quest’s expansion of both the embedded AI capability across products in their software portfolio and AI data readiness technology to enable enterprises to fully realize the promise of AI. Key initiatives will begin rolling out immediately, including the new Quest Software Center for Advanced Architecture. As part of this ground-breaking initiative, engineers will develop next-generation solutions for both AI data management and governance and agentic AI to identify and respond to cyber threats at machine speed.

Quest is also investing in building a world-class partner ecosystem specifically for the AI revolution, with specialized solution paths for data partners, identity security specialists, and Microsoft platform integrators working with Active Directory and EntraID environments.

 

About Quest Software

Quest Software creates technology and solutions that build the foundation for enterprise AI. Focused on data management and governance, identity security and platform modernization, Quest helps organizations address their most pressing challenges and make the promise of AI a reality.  Around the globe, more than 130,000 companies including over 90% of the Fortune 500 count on Quest Software.  For more information, visit www.quest.com or follow Quest Software on X (formerly Twitter) and LinkedIn.

 

About One Identity

An independent and standalone business within Quest Software helps organizations get identity and access management (IAM) right. With a unique combination of offerings including a portfolio of identity governance, access management and privileged management, and identity as a service that help organizations reach their full potential, unimpeded by security yet safeguarded against threats. One Identity has proven to be a company unequalled in its commitment to its customers’ long-term IAM success. More than 7,500 customers worldwide depend on One Identity solutions to manage more than 125 million identities, enhancing their agility and efficiency while securing access to their data — wherever it might reside. For more information, visit https://www.oneidentity.com/.

 

About Clearlake

Clearlake Capital Group, L.P. is an investment firm founded in 2006 operating integrated businesses across private equity, credit and other related strategies. With a sector-focused, approach, the firm seeks to partner with experienced management teams by providing patient, long-term capital to dynamic businesses that can benefit from Clearlake’s operational approach, O.P.S.® The firm’s core private equity target sectors are technology, industrials, and consumer. Clearlake currently has over $90 billion of assets under management and its senior investment principals have led or co-led over 400 investments, and has deployed over $57 billion in liquid and illiquid credit investments globally. The firm is headquartered in Santa Monica, CA with affiliates in Dallas, TX, London, UK, Dublin, Ireland, Luxembourg, Abu Dhabi, UAE, and Singapore. More information is available at www.clearlake.com.

 

Media Contacts:
For Quest:

Slava Balykov

slava.balykov@quest.com

 

For Clearlake:

Jennifer Hurson

Jhurson@lambert.com

Categories: News

Tags: